Sep 30, 2026, 2:32 PMPharmaceuticals
Eli Lilly’s Zepbound and Amylin Combination Delivers Up to 23% Weight Loss
Eli Lilly’s experimental amylin drug, added to Zepbound, helped people lose up to 23% of weight but increased side effects; details remain very limited.
Listen to this briefingAudio briefing
Summary
MarketWatch reported on September 30, 2026, that adding Eli Lilly’s experimental amylin drug to Zepbound helped people lose up to 23% of their weight, although the combination produced more side effects.
Lilly is studying whether the candidate can support weight loss and diabetes management similarly to GLP-1 therapies. Only a short feed summary was available, with no drug name, trial design, participant count, treatment duration, adverse-event rates or next milestones disclosed.
Positives
- Up to 23% weight loss was reported when Eli Lilly’s experimental amylin candidate was added to Zepbound.
- Eli Lilly is evaluating the candidate for both weight loss and diabetes management.
- The amylin program targets benefits similar to those associated with GLP-1 therapies.
Risks & concerns
- More side effects occurred when the experimental amylin drug was combined with Zepbound.
- The amylin candidate remains experimental, and the available summary provided no development or regulatory timeline.
- The limited feed omitted trial size, duration, adverse-event frequencies and other data needed to assess the result fully.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/adding-lillys-new-drug-to-zepbound-helped-people-lose-up-to-23-of-their-weight-but-there-were-more-side-effects-b7b7c6c0?mod=mw_rss_topstories
Read full article
